Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy

Preclinical data show IV administration of a next-generation gene therapy produced dose-dependent replacement of syntaxin-binding protein 1 (STXBP1) throughout the brain, with efficacy predictive of clinical relevance lasting at least 12 months post therapeutic intervention Data to be showcased in an oral presentation at Epilepsy Therapies & Diagnostics Development Symposium today THOUSAND OAKS, Calif., June … Read more